Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




Company presents its forward-oriented range of solutions

(Jena, September 12th, 2008) Look forward - this is Carl Zeiss
Meditec's motto for the leading European Congress for Ophthalmology
ESCRS (European Society of Cataract and Refractive Surgeons). "In the
last five years Carl Zeiss Meditec has experienced remarkable
development. We've turned into an integrated medical technology
company with twelve locations and more than 2000 employees worldwide.
And we are now looking forward to maximising the dynamic innovative
force which forms the basis of our strong reputation by harnessing
the synergies of the extended company. Look forward - applies not
only to us but also to our customers. Together with physicians we are
pressing ahead with rapid developments in surgical ophthalmology. We
will be taking a further step into the future for our customers with
first-rate new products which fit seamlessly into our integrated
range of solutions," said Dr. Michael Kaschke, President and CEO of
Carl Zeiss Meditec, explaining the company's strategy at this year's
congress.
Carl Zeiss Meditec is using congresses such as the ESCRS, to be held
from 13 to 17 September 2008 in Berlin (Germany), not only to present
the major new developments; the company will also be offering doctors
and media representatives the opportunity to discuss urgent medical
issues and possible solutions to these challenges in an informed
environment. Numerous wetlabs and scientific workshops will be
serving as discussion forums alongside the innovation symposium.
There will be demonstration operations performed by leading surgeons
which can be monitored live on screens. In its "Meet the Experts"
series, internationally recognised specialists will be reporting on
their experience with Carl Zeiss Meditec products.
The latest generations of intraocular lenses (IOLs) are just some of
the new products. With incisions of less than 1.5 mm, Acri.LISA® and
Acri.LISAtoric are the first intraocular lenses for true micro
incision (MICS) refractive cataract surgery in the world. "These
toric and multifocal IOLs are our response to the continually rising
demands patients place on their eye surgeons. The technique of
microincision dissolves the boundaries between cataract and
refractive surgery. In the Acri.LISA® we have brought surgeons' dream
of avoiding astigmatism during the procedure one step closer, and are
giving the patients the possibility of a life free from spectacles,"
says Dr. Kaschke, explaining the benefits of this groundbreaking
achievement. "We are convinced that offering the complete premium IOL
portfolio will put the company at the forefront of microincision
surgery".
The IOLMaster is used for eye measurement and has successfully
established itself on the market over the last ten years. A new,
optimised version will be presented at the ESCRS, setting a new
benchmark in biometry. The latest generation allows ophthalmologists
and their patients to make even more precise and individualised
preparation for artificial lens implantation.
The OPMI Lumera is a surgical microscope which was developed
specifically for ophthalmic surgery. Ever since its launch it has
received an overwhelmingly positive response from specialists. Thanks
to its patented SCI(TM) technology, high-contrast details in the eye
can now be discerned with an unprecedented depth of field. Physicians
receive further workflow support in the OR in the form of an
information and documentation system specially developed for eye
surgery. This is about to receive its European launch at the ESCRS.
CALLISTO Eye will present operation-related data at the push of a
button. Work loads will fall, information security will rise.
CALLISTO Eye also allows the entire operation to be documented in the
form of a video recording, i.e. each step before, during and after
the operation can be reviewed and reproduced.
In Berlin Carl Zeiss Meditec will be celebrating the first
anniversary of the installation of the innovative VisuMax®
femtosecond laser in the private practices of refractive surgeons. In
combination with the high-end MEL 80(TM) excimer laser and the
CRS-Master®, the VisuMax® forms a perfectly integrated family of
devices for refractive surgery. The system has now been installed in
practices al over the world and has received exceptionally positive
assessments from users. The ESCRS will also see the unveiling of the
new MEL 80(TM) Eye Tracker with a sample rate of 1kHz. This reduces
the reaction time of the Eye Tracker by half and optimises the
correct positioning of the laser spot. Further applications of the
VisuMax laser system are in preparation. Initial study reports have
now been published and the new applications can be discussed with
experts in Berlin.
A major new diagnostic device is the optical coherence tomographer
CirrusTM HD-OCT, exploiting the full potential of spectral domain
technology. Quick and easy to operate, it provides unique views of
the retina thanks to precision segmentation algorithms and high
quality live images, thereby forming the best possible basis for
reliable diagnosis and treatment decisions for retinal disorders.
The ESCRS (European Society of Cataract and Refractive Surgeons) is
an association of European eye surgeons which is at the cutting edge
of developments in surgery on the anterior part of the eye. The
society, founded in 1991, counts 4,000 members from 90 countries
worldwide. ESCRS congresses meanwhile make a vital contribution to
the exchange of specialized knowledge and expertise between eye
specialists.

Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's
leading medical technology companies. This market position is based
on over 160 years of experience in optical innovation.
The company has two primary areas of activitiy: In the field of
ophthalmology Carl Zeiss Meditec offers integrated solutions for
treating the four main eye diseases: vision defects (refraction),
cataracts, glaucoma and retinal disorders. The company's system
solutions are employed in all phases of the disease management, from
diagnosis to treatment and follow-up. Carl Zeiss Meditec has always
applied its technological expertise to product innovations. These
innovations range from basic systems such as slit lamps and fundus
cameras to standard setting diagnostic systems such as the Humphrey®
Field Analyzer, the Cirrus(TM) HD-OCT and the IOLMaster®, through to
the surgical microscopes and innovative treatment systems in
refractive laser surgery. The product portfolio in ophthalmic surgery
is rounded off by intraocular lenses and consumables.
In the field of neuro and ENT surgery, Carl Zeiss Meditec is the
world's leading provider of surgical microscopes and microsurgical
visualisation solutions for a very broad range of applications, such
as tumor and vascular surgery in the head region and/or spinal
surgery. The most recent example of our innovative performance in the
area of microsurgery is the OPMI Pentero® visualisation system, which
allows efficient and ergonomic patient treatment. Carl Zeiss Meditec
will systematically expand its product range in this area and become
a solution provider in neuro and ENT surgery as well.
Carl Zeiss Meditec's medical technology portfolio is rounded off by
visualisation systems for doctors in private practice and promising
future technologies such as intraoperative radiation therapy, which
allows the targeted treatment of breast cancer and brain cancer
directly during surgery.
An aging global population, rising expectations of doctors and
patients, together with innovative treatment methods in medical
technology are expected to promote market growth in the long term.
Carl Zeiss Meditec holds an optimum position for future developments
in the health sector. The company focuses its solution portfolio on
the three medical challenges with a significant social and economic
impact: loss of mobility, vision and cognitive abilities. The goal is
to deliver technologies and application-oriented solutions that allow
doctors to improve the quality of life of their patients and to
further improve the efficiency of diagnosis and treatment.
Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in
Germany (Carl Zeiss Surgical GmbH, Carl Zeiss Meditec
Vertriebsgesellschaft mbH, Acri.Tec AG and Carl Zeiss Medical
Software GmbH), the USA (Carl Zeiss Meditec, Inc., Dublin
California), in Japan (Carl Zeiss Meditec Co., Ltd., Tokyo), Spain
(Carl Zeiss Meditec Iberia S.A., Madrid) and France (Carl Zeiss
Meditec S.A.S, La Rochelle, and Carl Zeiss Meditec France SAS, Le
Pecq).
Thirty-five percent of the Carl Zeiss Meditec shares are in free
float. The remaining 65 percent are held by Carl Zeiss, one of the
world's leading international groups engaged in the optical and
opto-electronics industry.

Contact
Kerstin Nössig/ Public Relations
Goeschwitzer Straße 51-52
07745 Jena, Germany
Telefon: +49 (0) 36 41 - 2 20 - 3 35
Telefax: +49 (0) 36 41 - 2 20 - 1 12
E-Mail: k.noessig@meditec.zeiss.com
Web:    http://www.meditec.zeiss.com


 
--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

WKN: 
531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share, 
TecDAX;
Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse 
Stuttgart, 
Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, 
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr 
in Niedersächsische Börse zu Hannover, 
Prime Standard in Frankfurter Wertpapierbörse, Geregelter Markt in 
Frankfurter Wertpapierbörse;



Copyright © Hugin AS 2008. All rights reserved.